Latest Antibiotic-resistant bacteria Stories
SAN DIEGO, May 17, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including...
ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights. Operational Highlights Emphasis on C. difficile (C. diff) Infection Prevention (SYN-004) In the U.S. each year, 24 million patients are administered IV antibiotics([1]) which may be...
Padmore Books author, Ila Monroe, writes a thriller to spark a conversation about deadly infections that occur daily in the medical wards, but go unreported. Miami, Florida (PRWEB) May 14, 2013 Golden Plague, by Ila Monroe, is a work of fiction where the villains are hospital directors and managers of pharmaceutical companies covering up a sinister set of occurrences, and the protagonists, three young adults, trying to stay alive. It depicts a modern day reality which is plaguing public...
Now Registered Nationwide, Breakthrough Disinfectant Poised to Change Epidemic's Course OREM, Utah, May 13, 2013 /PRNewswire/ -- sBioMed(®)( )announced today that STERIPLEX SD(®) has been registered by the U.S. Environmental Protection Agency (EPA) and is now cleared for sale in all 50 states. STERIPLEX SD is the first and only broad-spectrum, one-step cleaner/disinfectant that offers a powerful combination of safety and efficacy to eliminate healthcare associated infections...
Certain types of anti-depressants have been linked to an increase in the risk of Clostridium difficile infection (CDI) finds a study in BioMed Central's open access journal BMC Medicine. Awareness of this link should improve identification and early treatment of CDI. CDI is one of the most common hospital acquired infections and is responsible for more than 7000 deaths annually in the USA alone. Several types of medications are thought to increase risk of CDI, including anti-depressants,...
A handheld diagnostic device that Massachusetts General Hospital (MGH) investigators first developed to diagnose cancer has been adapted to rapidly diagnose tuberculosis (TB) and other important infectious bacteria. Two papers appearing in the journals Nature Communications and Nature Nanotechnology describe portable devices that combine microfluidic technology with nuclear magnetic resonance (NMR) to not only diagnose these important infections but also determine the presence of...
NEW YORK, May 2, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") today announced it will present the results of two in vitro studies investigating the antimicrobial properties of the Company's SilverSeal(®) hydrogel dressing. Data from these studies indicate that SilverSeal may be capable of rapid and sustained efficacy in managing the occurrence of wound contamination by reducing the bioburden from multiple bacterial pathogens and by sustaining this...
Growing Competition Among Highly Effective Therapies Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., April 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European infectious disease specialists agree that effect on recurrence rate is one of the drug attributes that most influences their...
EXTON, Pa., April 22, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections (CDI). CDI is a common and dangerous gastrointestinal...
DURHAM, N.C., April 19, 2013 /PRNewswire/ -- A recent study funded by Centers for Disease Control and Prevention (CDC) Epicenters Program and published in Infection Control and Hospital Epidemiology (Deverick H. Anderson, M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. -...
